Aldesleukin Completed Phase 1 / 2 Trials for Melanoma (Skin) / Intraocular Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT00470015Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
NCT00005943Gene Therapy in Treating Patients With Metastatic Melanoma
NCT00019175Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma
NCT00045149Biological Therapy in Treating Patients With Metastatic Melanoma
NCT00091104Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma
NCT00085462Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma